Note 14 - Income Taxes - Deferred Tax Assets and Liabilities (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Net operating loss carryforwards	$ 7,547,296
Stock option compensation	2,720,186
Orphan Drug credits	1,218,069
Capitalized start-up costs and other	4,690,843
Valuation allowance	(16,176,394)	$ 0
Net deferred tax asset
Intangible assets	(3,279,363)
Net deferred tax liability	$ (3,279,363)